Phase I study finished

We have completed phase I study with JAK kinase inhibitors.

The JAK family of non-receptor tyrosine kinases regulates the transduction of signals from cytokines and their receptors by activating STAT transcription factors and modulating the expression of STAT-dependent genes. Excessive activation of the JAK/STAT pathway has been confirmed in immune-related diseases, where JAK kinases participate in the induction and maintenance of inflammation. The development of therapy based on the inhibition of JAK family kinases has applications in many areas: oncology by inhibiting excessive cell growth and proliferation (e.g. JAK2 inhibitor in myeloproliferative syndromes and leukemias), in immunology by regulating the secretion of pro-inflammatory cytokines (e.g. JAK1 inhibitor in chronic lung diseases inflammatory) and in transplantology due to its immunosuppressive effect (inhibition of JAK3 kinase). 

The study was performed with healthy volunteers in two parts: A (single ascending dose) and B (multiple ascending dose), with different doses and placebo control.

Go back

News

Merry Christmas and Happy New Year

Let the magical night of Christmas Eve bring peace and joy. Let every moment of Christmas live with its own beauty, and bestows the New Year with prosperity and happiness.

Read more …

COVID -19 Antigen Tests:

On 31st of October 2020, the Chief Sanitary Inspectorate confirmed that the antigen cassette tests are the same basis for determining the SARS-CoV-2 ...

Read more …

BRG team participated in BIO-Europe®

On 26th -27th  of October BRG team participated in BIO-Europe® the largest partnering conference in Europe dedicated to the global biotechnology industry. 

Read more …

BRG Team participated in the official opening of the Celon Pharma Research and Development Center

On September 28, 2020 BRG Team participated in the official opening of the Celon Pharma Research and Development Center

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.

 

scroll to top ▲